Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Decreases By 39.9%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 49,784 shares, a drop of 39.9% from the June 30th total of 82,827 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 87,989 shares, the short-interest ratio is presently 0.6 days.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 1.95% of the stock is currently owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Trading Up 0.5%

NASDAQ SNOA traded up $0.01 during mid-day trading on Thursday, hitting $1.10. The company’s stock had a trading volume of 2,053 shares, compared to its average volume of 119,929. The firm has a market capitalization of $5.29 million, a price-to-earnings ratio of -0.58 and a beta of 1.27. The company’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.98. Sonoma Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The business had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.